Jannusch, Kai http://orcid.org/0000-0001-7285-3430
Bruckmann, Nils Martin
Morawitz, Janna
Boschheidgen, Matthias
Quick, Harald H.
Herrmann, Ken
Fendler, Wolfgang P.
Umutlu, Lale
Stuschke, Martin
Hadaschik, Boris
Antoch, Gerald
Schimmöller, Lars
Kirchner, Julian
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Received: 23 August 2023
Revised: 7 October 2023
Accepted: 10 October 2023
First Online: 1 December 2023
Declarations
:
: The scientific guarantor of this publication is Kai Jannusch.
: Boris Hadaschik <i>reports personal fees and non-financial support from ABX, Amgen, AAA/Novartis, Bayer, BMS, Janssen, Lightpoint Medical, Inc, MSD, and Pfizer, grants from German Research Foundation, all outside the submitted work.</i>Wolfgang P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Calyx (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker), and Telix (speaker) outside of the submitted work.The other authors have no relevant financial or non-financial interests to disclose.
: One of the authors has significant statistical expertise.
: Written informed consent was obtained from all patients in this study.
: Institutional Review Board approval was obtained (University of Duisburg-Essen (study number 11–4822-BO)).
: No study subjects or cohorts have been previously reported.
: • Retrospective• Diagnostic or prognostic study• Performed at one institution